LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Alkermes PLC

Closed

SectorHealthcare

29.82 -3.06

Overview

Share price change

24h

Current

Min

29.48

Max

30.66

Key metrics

By Trading Economics

Income

-124M

22M

Sales

-123M

307M

P/E

Sector Avg

15.117

51.748

EPS

0.291

Profit margin

7.329

Employees

1,800

EBITDA

-168M

14M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+29.27% upside

Dividends

By Dow Jones

Next Earnings

23 lip 2025

Market Stats

By TradingEconomics

Market Cap

-596M

5.2B

Previous open

32.88

Previous close

29.82

News Sentiment

By Acuity

50%

50%

177 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Alkermes PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 cze 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380 Million

13 cze 2025, 23:50 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 cze 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 cze 2025, 23:09 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 cze 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 cze 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380M

13 cze 2025, 22:04 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 cze 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 cze 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Bunge: Outside Date Extended to July 3

13 cze 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 cze 2025, 21:34 UTC

Acquisitions, Mergers, Takeovers

Bunge Gets Mexico Approval for Viterra Deal

13 cze 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bunge Gets China Approval for Viterra Deal

13 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 cze 2025, 20:45 UTC

Acquisitions, Mergers, Takeovers

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 cze 2025, 20:34 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 cze 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 cze 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 cze 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 cze 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

13 cze 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

13 cze 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 cze 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

13 cze 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 cze 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 cze 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 cze 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

13 cze 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

29.27% upside

12 Months Forecast

Average 39.79 USD  29.27%

High 52 USD

Low 30 USD

Based on 14 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

8

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

27.95 / 30.91Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

177 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.